The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation

Current Alzheimer Research

Volumn 9, Issue 9, 2012, Pages 1010-1029

  Anand, Akshay ^a   Banik, Avijit ^a   Thakur, Keshav ^a   Masters, Colin L ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Dementia; Memory disorder; Preclinical; Spatial memory

Indexed keywords

ALCOHOL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; CAPTOPRIL; CEREBROLYSIN; DEANOL; DEFEROXAMINE; DOMOIC ACID; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; IBOTENIC ACID; IDEBENONE; INDELOXAZINE; INDOMETACIN; KAINIC ACID; LOSARTAN; MEMANTINE; NICERGOLINE; PHENYTOIN; PIRACETAM; PREDNISONE; PROPRANOLOL; RIVASTIGMINE; ROCEPAFANT; TACRINE; UNINDEXED DRUG; VINPOCETINE; XANTHINOL NICOTINATE;

ALZHEIMER DISEASE; ANIMAL MODEL; APOPTOSIS; CELL PROLIFERATION; COGNITION; COGNITIVE DEFECT; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DEPOLARIZATION; DIFFUSE LEWY BODY DISEASE; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; EXCITATORY POSTSYNAPTIC POTENTIAL; FRONTOTEMPORAL DEMENTIA; GINKGO BILOBA; HUMAN; HUNTINGTON CHOREA; IMMUNOTHERAPY; LEARNING; LONG TERM DEPRESSION; LONG TERM MEMORY; LONG TERM POTENTIATION; MAZE TEST; MEMORY; MESENCHYMAL STEM CELL TRANSPLANTATION; NERVE CELL PLASTICITY; NEURAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT TERM MEMORY; TRADITIONAL MEDICINE; TRANSIENT GLOBAL AMNESIA; TRAUMATIC BRAIN INJURY; WERNICKE KORSAKOFF SYNDROME;

ALZHEIMER DISEASE; ANIMALS; DEMENTIA; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS;

EID: 84870165746     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512803569055     Document Type: Review

References (222)

1. Bernstein DA, Clarke-Stewart A, Roy EJ, Srull TK, Wickens CD. Psychology (3rd ed.). Boston: Houghton-Mifflin Co. pp 286-321 (1994).
2. Fauci AS, Braunwald E, Kasper DL. Harrison's Principles of Internal Medicine. 17th ed. United States: McGraw-Hill Professional (2008).
3. Thomas DB. Memory loss and dementia. (Ed: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL). The McGraw-Hill Co. Harrison's principles of internal medicine 15 148-155 (2001).
4. Gao J, Prough DS, McAdoo DJ, Grady JJ, Parsley MO, Ma L, et al. Transplantation of primed human fetal neural stem cells improves cognitive function in rats after traumatic brain injury. Exp Neurol 201: 281-292 (2006).
5. Tang J, Xu H, Fan X, Li D, Rancourt D, Zhou G, et al. Embryonic stem cell-derived neural precursor cells improve memory dysfunction in Ab(1-40) injured rats. Neurosci Res 62(2): 86-96 (2008).
6. Zhang WN, Bast T, Feldon J. The ventral hippocampus and fear conditioning in rats: different anterograde amnesias of fear after infusion of N-methyl-D-aspartate or its noncompetitive antagonist MK-801 into the ventral hippocampus. Behav Brain Res 126: 159-174 (2001).
7. Chin J. Selecting a mouse model of Alzheimer's disease. Methods Mol Bio 670: 169-189 (2011).
8. Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry 20: 11-21 (1957).
9. Scoville WB. The limbic lobe in man. J Neurosurg 11: 64-66 (1954).
10. Squire LR. Memory and the hippocampus: A synthesis from findings with rats, monkeys, and humans. Psychol Rev 99: 195-231 (1992).
11. Eichenbaum H, Cohen NJ. From conditioning to conscious recollection: memory systems of the brain. Oxford Univ Press, London (2001).
12. Fujimichi R, Naya Y, Miyashita Y. Associative memory: Representation, activation, and cognitive control. Cogn Neurosci 3: 905-918 (2004).
13. Wang H, Wagner JJ. Priming-induced shift in synaptic plasticity in the rat hippocampus. J Neurophysiol 82: 2024-2028 (1999).
14. Hebb, DO. The Organization of Behavior: A Neuropsychological Theory. New York: John Wiley (1949).
15. Cajal SR. La fine structure des centres nerveux. Proc R. Soc Lond 55: 444-468 (1894).
16. Kandel ER, Schwartz JH. Molecular biology of learning: modulation of transmitter release. Science 218: 433-443 (1982).
17. Hawkins RD, Kandel ER, Bailey CH. Molecular mechanism of memory storage in Aplysia. Biol Bull 210: 174-191 (2006).
18. Bartsch D, Ghirardi M, Skehel PA, Karl KA, Herder SP, Chen M, et al. Aplysia CREB2 represses long-term facilitation: relief of repression converts transient facilitation into long-term functional and structural change. Cell 83: 979-992 (1995).
19. Malenka R, Bear M. LTP and LTD: an embarrassment of riches. Neuron 44(1): 5-21 (2004).
20. Sweatt J. Toward a molecular explanation for long-term potentiation. Learn Mem 6 (5): 399-416 (1999).
21. Dundee JW. The effect of drugs on memory. SAAD Dig 5: 5-9 (1982).
22. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith IM, et al. Amyloid-protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine 14: 837-842 (2008).
23. Geldmacher DS, Whitehouse PJ. Evaluation of dementia. N Eng J Med 5: 330-335 (1996).
24. Hofman A, Rocca WA, Brayne C, Breteler MM, Clarke M, Cooper B, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 20: 736-748 (1991).
25. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11): S4-S9 (2000).
26. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. Lancet Neurol 2: 89-98 (2003).
27. Web MD. Memory loss symptoms & signs index. In: MedicineNet, Inc.
28. Basu S, Bhattacharya KB. Dementia Current Status. Post Grad Med 17: 543-551 (2003).
29. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3(3): 186-191 (2007).
30. Alzheimer's and Related Disorders Society of India (ARDSI), (2008).
31. Graeber MB, Mehraein P. Reanalysis of the first case of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 249 Suppl 3:10-13 (1999).
32. Neet KE, Thinakaran G. Thematic minireview series on the molecular basis of Alzheimer disease. J Biol Chem. 283(44): 29613-26914 (2008).
33. Micheau J, Marighetto A. Acetylcholine and memory: a long, complex and chaotic but still living relationship. Behav Brain Res. 221(2): 424-429 (2011).
34. McNamara RK, Skelton RW. Baclofen, a selective GABAB receptor agonist, dose-dependently impairs spatial learning in rats. Pharmacol Biochem Behav 53: 303-308 (1996).
35. Ferry B, McGaugh JL. Role of amygdala norepinephrine in mediating stress hormone regulation of memory storage. Acta Pharmacol Sin 21: 481-493 (2000).
36. Sawaguchi T. The effects of dopamine and its antagonists on directional delay-period activity of prefrontal neurons in monkeys during an oculomotor delayed-response task. Neurosci Res 41: 115-128 (2001).
37. Hasenohrl RU, Kuhlen A, Frisch C, Galosi R, Brandao ML, Huston JP. Comparison of intra-accumbens injection of histamine with histamine H1-receptor antagonist chlorpheniramine in effects on reinforcement and memory parameters. Behav Brain Res 124: 203-211 (2001).
38. Filliat P, Blanchet G. Effects of TCP on spatial memory: comparison with MK-801. Pharmacol Biochem Behav 51: 429-434 (1995).
39. Paul V, Ekambaram P. Involvement of nitric oxide in learning & memory processes. Indian J Med Res. 133(5): 471-478 (2011).
40. Bannerman DM, Good MA, Butcher SP, Ramsay M, Morris RG. Distinct components of spatial learning revealed by prior training and NMDA receptor blockade. Nature 378: 182-186 (1995).
41. Morris RG. Synaptic plasticity and learning: selective impairment of learning rats and blockade of long-term potentiation in vivo by the N-methyl-D-aspartate receptor antagonist AP5. J Neurosci 9(9): 3040-3057 (1989).
42. Saucier D, Cain DP. Spatial learning without NMDA receptordependent long-term potentiation. Nature 378: 186-189 (1995).
43. Stringer JL, Greenfield LJ, Hackett JT, Guyenet PG. Blockade of long-term potentiation by phencyclidine and sigma opiates in the hippocampus in vivo and in vitro. Brain Res 280: 127-138 (1983).
44. Fadda P, Robinson L, Fratta W, Pertwee RG, Riedel G. Scopolamine and MK801-induced working memory deficits in rats are not reversed by CBD-rich cannabis extracts. Behav Brain Res 168(2): 307-311 (2006).
45. Holscher C. Inhibitors of metabotropic glutamate receptors produce amnestic effects in chicks. Neuroreport 5: 1037-1040 (1994).
46. Hawkins RD, Son H, Arancio O. Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. Prog Brain Res 118: 155-172 (1998).
47. Yamada K. Role of nitric oxide in learning and memory processes. Nippon Yakurigaku Zasshi 111: 87-96 (1998).
48. Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Can J Clin Pharmacol 6: 69-83 (1999)
49. Kant GJ, Wright WL, Robinson TN, D'Angelo CP. Effects of MK- 801 on learning and memory as assessed using a novel water maze. Pharmacol Biochem Behav 39: 479-485 (1991).
50. Ennaceur A, Meliani K. Effects of physostigmine and scopolamine on rats' performances in object-recognition and radial-maze tests. Psychopharmacology (Berl) 109: 321-330 (1992).
51. Wesnes K, Warburton DM. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology (Berl) 82:147-150 (1984).
52. Ghoneim MM, Mewaldt SP. Effects of diazepam and scopolamine on storage, retrieval and organizational processes in memory. Psychopharmacologia 44: 257-262 (1975).
53. Terry AV, Jr., Buccafusco JJ, Jackson WJ. Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys. Pharmacol Biochem Behav 45: 925-929 (1993).
54. Schifano F, Curran HV. Pharmacological models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on word valence ratings, priming and recall. Psychopharmacology (Berl) 115: 430-434 (1994).
55. Kandel ER, Schwartz JH, Jessell TM. Principles of neural science. New York: McGraw-Hill (2000).
56. Kim YH, Lee Y, Kim D, Jung MW, Lee CJ. Scopolamine-induced learning impairment reversed by physostigmine in zebrafish. Neurosci Res 67(2): 156-161 (2010).
57. Ulrich S, Christoph H. Tiagabine, a γ-amino-butyric acid transporter inhibitor impairs spatial learning of rats in the Morris watermaze. Behav Brain Res 133: 391-394 (2002).
58. Castellano C, Introini-Collison IB, Pavone F, McGaugh JL. Effects of naloxone and naltrexone on memory consolidation in CD1 mice: involvement of GABAergic mechanisms. Pharmacol Biochem Behav 32: 563-567 (1989).
59. Thiebot MH. Some evidence for amnesic-like effects of benzodiazepines in animals. Neurosci Biobehav Rev 9: 95-100 (1985).
60. Gibbs ME, Maksel D, Gibbs Z, Hou X, Summers RJ, Small DH. Memory loss caused by beta-amyloid protein is rescued by a beta(3)-adrenoceptor agonist. Neurobiol Aging 31(4): 614-624 (2010).
61. Ciriza I, Carrero P, Frye CA, Garcia-Segura LM. Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective. J Neurobiol 66: 916-928 (2006).
62. Kim JH, Hahm DH, Lee HJ, Pyun KH, Shim I. Acori graminei rhizoma ameliorated ibotenic acid-induced amnesia in rats. Evid Based Complement Alternat Med. 6(4): 457-464 (2009).
63. Sutherland RJ, Hoesing JM, Whishaw IQ. Domoic acid, an environmental toxin, produces hippocampal damage and severe memory impairment. Neurosci Lett 120(2): 221-223 (1990)
64. Selkoe DJ. Normal and abnormal biology of the γ-amyloid precursor protein. A Rev Neurosci 17: 489-517 (1994).
65. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid γ-protein: reversal by tachykinin neuropeptides. Science 250: 279-282 (1990).
66. Behl C, Davis JB, Klier FG, Chubert D. Amyloid γ peptide induces necrosis rather than apoptosis. Brain Res 645: 253-264 (1994).
67. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. Apoptosis is induced by γ-amyloid in cultured central nervous system neurons. Proc natn Acad Sci U.S.A. 90: 7951-7955 (1993).
68. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. γ-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12: 376-389 (1992).
69. Busciglio J, Lorenzo A, Yeh J, Yankner BA. γ-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14: 879-888 (1995).
70. Kar S, Slowikowski SP, Westaway D. Interactions between betaamyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci 29: 427-441 (2004).
71. Jarrett JT, Lansbury Jr. PT. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1055-1058 (1993).
72. Yamaguchi T, Yagi H, Goto Y, Matsuzaki K, Hoshino M. A disulfide-linked amyloid-beta peptide dimer forms a protofibril-like oligomer through a distinct pathway from amyloid fibril formation. Biochemistry. 49(33): 7100-7107 (2010).
73. Innocent N, Evans N, Hille C, Wonnacott S. Oligomerisation differentially affects the acute and chronic actions of amyloid-beta in vitro. Neuropharmacology. 59(4-5):343-352 (2010).
74. Wang Q, Matsumoto Y, Shindo T, Miyake K, Shindo A, Kawanishi M, et al. Neural stem cells transplantation in cortex in a mouse model of Alzheimer's disease. J Med Invest 53(1-2): 61-69 (2006).
75. Srivastava N, Seth K, Srivastava N, Khanna VK, Agrawal AK. Functional restoration using basic fibroblast growth factor (bFGF) infusion in kainic acid induced cognitive dysfunction in rat: neurobehavioural and neurochemical studies. Neurochem Res 33: 1169-1177 (2008).
76. Grant KS, Burbacher TM, Faustman EM, Gratttan L. Domoic acid: neurobehavioral consequences of exposure to a prevalent marine biotoxin. Neurotoxicol Teratol 32(2): 132-141 (2010).
77. Nijjar MS, Nijjar SS. Domoic acid-induced neurodegeneration resulting in memory loss is mediated by Ca2+ overload and inhibition of Ca2+ + calmodulin-stimulated adenylate cyclase in rat brain. Int J Mol Med 6(4): 377-389 (2000).
78. Köhler C, Schwarcz R. Comparison of ibotenate and kainate neurotoxicity in rat brain: a histological study. Neurosci 8(4): 819-835 (1983).
79. Matthews DB, Best PJ. Fimbria/fornix lesions facilitate the learning of a nonspatial task. Psychon Bull Rev 2: 113-116 (1995).
80. Melia, KR, Ryabinin AE, Corodimas KP, Wilson MC, Ledoux JE. Hippocampal-dependent learning and experience-dependent activation of the hippocampus are preferentially disrupted by ethanol. Neuroscience 74: 313-322 (1996).
81. White AM, Elek TM, Beltz TL, Best PJ. Spatial performance is more sensitive to ethanol than nonspatial performance regardless of cue proximity. Alcohol Clin Exp Res 22: 2102-2107 (1998).
82. Matthews DB, Ilgen M, White AM, Best PJ. Acute ethanol administration impairs spatial performance while facilitating nonspatial performance in rats. Neurobiol Learn Mem 72: 169-179 (1999).
83. Matthews DB, Simson PE, Best PJ. Ethanol alters spatial processing of hippocampal place cells: a mechanism for impaired navigation when intoxicated. Alcohol Clin Exp Res 20: 404-407 (1996).
84. White AM, Best PJ. Effects of ethanol on hippocampal place-cell and interneuron activity. Brain Res 876: 154-165 (2000).
85. Ryabinin AE, Miller MN, Durrant S. Effects of acute alcohol administration on object recognition learning in C57BL/6J mice. Pharmacol Biochem Behav 71: 307-312 (2002).
86. Chin J. Selecting a mouse model of Alzheimer's disease. Methods Mol Bio 670: 169-189 (2011).
87. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron 66: 631-645 (2010).
88. Games D, Buttini M, Kobayashi D, Schenk D, Seubert P. Mice as models: transgenic approaches and Alzhiemer's disease. J.Alzheimer's Dis 9(3 Suppl): 133-149 (2006).
89. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523-527 (1995).
90. Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol 33: 883-889 (1998).
91. Eriksen JL, Janus CG. Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav Genet 37: 79-100 (2007).
92. Morgan D. Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem Res 28(7): 1029-1034 (2003).
93. Higgins LS. Animal models of Alzheimer's disease. Mol Med Today 5(6): 274-276 (1999).
94. McBride SM, Choi CH, Schoenfeld BP, Bell AJ, Liebelt DA, Ferreiro D, et al. Pharmacological and genetic reversal of agedependent cognitive deficits attributable to decreased presenilin function. J Neurosci 30(28): 9510-9522 (2010).
95. Sun M, Qi Z. The human apoE7 and apoE4 transgenic mice models. Sci China Series C: Life Sci 44(6): 652-660 (2001).
96. Cai X, Golde TE, Younkin SG. Release of excess amyloid γ protein from a mutant amyloid γ protein precursor. Science 259: 514-516 (1993).
97. Lee HJ, Lee JK, Lee H, Carter JE, Chang JW, Oh W, et al. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer's disease mouse model through modulation of neuroinflammation. Neurobiol Aging 33(3): 588-602 (2012).
98. Spires-Jones TL, de Calignon A, Meyer-Luehmann M, Bacskai BJ, Hyman BT. Monitoring protein aggregation and toxicity in Alzheimer's disease mouse models using in vivo imaging. Methods. 53(3): 201-207 (2011).
99. Van Groen T, Kadish I, Wiesehan K, Funke SA, Willbold D. In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. Chemmedchem 4: 276-282 (2009).
100. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, et al. CD36 mediates the innate host response to beta-amyloid. J Exp Med 197: 1657-1666 (2003).
101. Meda L, Cassatella MA, Szendrei GI, Otvos L, Jr Baron P, Villalba M, et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374: 647-650 (1995).
102. Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 28: 11650-11661 (2008).
103. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49: 489-502 (2006).
104. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Tripletransgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421 (2003).
105. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440): 735-741 (1999).
106. Cai Y, Zhang XM, Macklin LN, Cai H, Luo XG, Oddo S, LaFerla FM, Struble RG, Rose GM, Patrylo PR, Yan XX. BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: Differential Aγ antibody labeling of early-onset axon terminal pathology. Neurotox Res 21(2): 160-174 (2012).
107. Liang B, Duan BY, Zhou XP, Gong JX, Luo ZG. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem 285(36): 27737-2744 (2010).
108. Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, et al. High betasecretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem 280: 32957-31967 (2005).
109. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8: 1343-1349 (2005).
110. Lavenex P, Amaral DG. Hippocampal-neocortical interaction: a hierarchy of associativity. Hippocampus 10: 420-430 (2000).
111. O'Keefe J, Nadel L. The hippocampus as a cognitive map. Oxford University Press, London (1978).
112. Manns JR, Hopkins RO, Reed JM, Kitchener EG, Squire LR. Recognition memory and the human hippocampus. Neuron 37: 171-180 (2003).
113. Zola SM, Squire LR, Teng E, Stefanacci L, Buffalo EA, Clark RE. Impaired recognition memory in monkeys after damage limited to the hippocampal region. J Neurosci 20: 451-463 (2000).
114. Nemanic S, Alvarado MC, Bachevalier J. The hippocampal/ parahippocampal regions and recognition memory: insights from visual paired comparison versus object delayed nonmatching in monkeys. J Neurosci 24: 2013-2026 (2004).
115. Clark RE, Zola SM, Squire LR. Impaired recognition memory in rats after damage to the hippocampus. J Neurosci 20: 8853-8860 (2000).
116. Gould TJ, Rowe WB, Heman KL, Mesches MH, Young DA, Rose GM, et al. Effects of hippocampal lesions on patterned motor learning in the rat. Brain Res Bull 58: 581-586 (2002).
117. Moser EI, Moser MB, Andersen P. Spatial learning impairment parallels the magnitude of dorsal hippocampal lesions, but is hardly present following ventral lesions. J Neurosci 13: 3916-3925 (1993).
118. Moser MB, Moser EI, Forrest E, Andersen P, Morris RG. Spatial learning with a minislab in the dorsal hippocampus. Proc Natl Acad Sci USA. 92: 9697-9701 (1995).
119. Duva CA, Floresco SB, Wunderlich GR, Lao TL, Pinel JPJ, Phillips AG. Disruption of spatial but not object-recognition memory by neurotoxic lesions of the dorsal hippocampus in rats. Behav Neurosci 111: 1184-1196 (1997).
120. Solntseva SV, Nikitin VP. Reversible and irreversible stages in the development of amnesia after disruption of the reactivation of associative memory in snails. Neurosci Behav Physio 40(6): 679-686 (2010).
121. Xu X, Boshoven W, Lombardo B, Spranger J. Comparison of the amnestic effects of NMDA receptor antagonist MK-801 and nitric oxide synthase inhibitors: L-NAME and L-NOARG in goldfish. Behav Neurosci 112(4): 892-899 (1998).
122. Morris RGM, Garrud P, Rawlins JNP, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 297: 681-693 (1982).
123. Whishaw IQ, McKenna JE, Maaswinkel H. Hippocampal lesions and path integration. Curr Opin Neurobiol 7: 228-234 (1997).
124. Pearce JM, Robert AD, Good M. Hippocampal lesions disrupt navigation based on cognitive maps but not heading vectors. Nature 396: 75-77 (1998).
125. Brioni JD, Decker MW, Gamboa LP, Izquierdo I, McGaugh JL. Muscimol injections in the medial septum impair spatial learning. Brain Res 522: 227-234 (1990).
126. Decker MW, Majchrzak MJ, Anderson DJ. Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res 572: 281-285 (1992).
127. Rapp PR, Rosenberg RA, Gallagher M. An evaluation of spatial information processing in aged rats. Behav Neurosci 101: 3-12 (1987).
128. Vogel HG. Drug effects on learning and memory. In: Drug Discover and Evalution: Pharmacological Assays. (2nd Edition). Germany: Springer-Verlag Berlin Heidelberg. pp 595-643 (2002).
129. Calhoun ME. Mouse models of cognitive aging: Behavioral tasks and neural substrates. In J. L. Bizon, & A. G. Woods (Eds.), Animal Models of Human Cognitive Aging. New York: Humana Press (2009).
130. Salvin HE, McGreevy PD, Sachdev PS, Valenzuela MJ. The canine sand maze: an appetitive spatial memory paradigm sensitive to Age-related change in dogs. J Exp Anal Behav 95:109-118 (2011).
131. Haijima A, Ichitani Y. Anterograde and retrograde amnesia of place discrimination in retrosplenial cortex and hippocampal lesioned rats. Learn Mem 15(7): 477-482 (2008).
132. Pompl PN, Mullan MJ, Bjugstad K, Arendash GW. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer's disease. J Neurosci Methods 87(1): 87-95 (1999).
133. McNaughton BL, Barnes CA, Meltzer J, Sutherland RJ. Hippocampal granule cells are necessary for normal spatial learning but not for spatially selective pyramidal cell discharge. Exp Brain Res 76(3): 485-496 (1989).
134. Poucet B, Herrmann T, Buhot MC. Effects of short-lasting inactivations of the ventral hippocampus and medial septum on longterm and short-term acquisition of spatial information in rats. Behav Brain Res 44(1): 53-65 (1991).
135. Barnes CA, Nadel L, Honig WK. Spatial memory deficit in senescent rats. Can J Psychol 34(1): 29-39 (1980).
136. Netto CA, Izquierdo I. On how passive is inhibitory avoidance. Behav Neural Biol 43: 327-330 (1985).
137. Jarvik ME, Essmann WB. A simple one-trial learning situ ation in mice. Psychol Res 6: 290 (1960).
138. Zornetzer SF, Thompson R, Rogers J. Rapid forgetting in aged rats. Behav Neural Biol 36: 49-60 (1982).
139. Abdel-Hafez AA, Meselhy MR, Nakamura N, Hattori M, Watanabe H, Murakami Y, et al. Effects of paeoniflorin derivatives on scopolamine-induced amnesia using a passive avoidance task in mice; structure-activity relationship. Biol Pharm Bull 21: 1174-1179 (1998).
140. Kubanis P, Zornetzer SF. Age-related behavioral and neurobiological changes: a review with an emphasis on memory. Behav Neural Biol 31: 115-172 (1981).
141. Jarvik ME, Kopp R. An improved one-trial passive avoidance learning situation. Psychol Rep 21: 221-224 (1967).
142. King RA, Glasser RL. Duration of electroconvulsive shockinduced retrograde amnesia in rats. Physiol Behav 5: 335-339 (1970).
143. Hock FJ, Gerhards HJ, Wiemer G, Stechl J, Ruger W, Urbach H. Effect of novel compound, Hoe 065, upon impaired learning and memory in rodents. Eur J Pharmacol 171: 79-85 (1989).
144. Hock FJ. Involvement of nitric oxide-formation in the action of losartan (DuP 753): effects in an inhibitory avoidance model. Behav Brain Res 61: 163-167 (1994).
145. Javadi-Paydar M, Rayatnia F, Fakhraei N, Zakeri M, Mirazi N, Norouzi A, et al. Atorvastatin improved scopolamine-induced impairment in memory acquisition in mice: Involvement of nitric oxide. Brain Res (2011) [Epub ahead of print].
146. Tong XK, Lecrux C, Hamel E. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J Neurosci 32(14): 4705-4715 (2012).
147. Kurata T, Miyazaki K, Kozuki M, Panin VL, Morimoto N, Ohta Y, Nagai M, Ikeda Y, Matsuura T, Abe K. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res 1371: 161-170 (2011).
148. Kurata T, Miyazaki K, Kozuki M, Morimoto N, Ohta Y, Ikeda Y, Abe K. Progressive neurovascular disturbances in the Cerebral cortex of alzheimer's disease-model mice: protection by atorvastatin and pitavastatin Neuroscience 197: 358-368 (2011).
149. Herrnstein RJ. Method and theory in the study of avoidance. Psychol Rev 76: 49-69 (1969).
150. D'Amato MR. Experimental Psychology: Methodology, Psychophysics and Learning. New York: McGraw-Hill. pp 381-416 (1970).
151. Munn NJ. Handbook of psychological research on the tat. Boston: Houghton Mifflin Co. (1950).
152. Hock FJ, McGaugh JL. Enhancing effects of Hoe 175 on memory in mice. Psychopharmacology 86(1-2): 114-117 (1985).
153. Brandão ML, Troncoso AC, Melo L, Sandner G. Active avoidance learning using brain stimulation applied to the inferior colliculus as negative reinforcement in rats: Evidence for latent inhibition. Neuropsychobiology 35: 30-35 (1997).
154. Brush FR. Aversive Conditioning and Learning. New York and London: Academic Press (1971).
155. Bliss TV, Collingridge GL. A synaptic model of memory: longterm potentiation in the hippocampus. Nature 361: 31-39 (1993).
156. Takeuchi T, Fukumoto Y, Harada E. Influence of a dietary n-3 fatty acid deficiency on the cerebral catecholamine contents, EEG and learning ability in rat. Behav Brain Res 131(1-2): 193-203 (2002).
157. van Duijin CM. Epidemiology of the dementias: recent developments and new approaches. J Neurol Neurosurg Psychiatry 60: 478-488 (1996).
158. Rang HP, Dale MM, Ritter JM. Neurodegenerative disorder: Dementia and Alzheimer's disease. Pharmacology 3: 522-527 (1995).
159. Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol 2: 503-505 (2003).
160. Minkeviciene R, Banerjee P, Tanila HJ. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. Pharmacol Exp Ther 311: 677-682 (2004).
161. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 60: 110-118 (2006).
162. Szilagyi AK. Dementia: current research results, practical perspectives. Orv Hetil 126: 499-506 (1985).
163. Gorthi SP, Venkatraman S. Dementia-Current Perspectives. Neurosci today 6: 44-152 (2000).
164. Nagy IZ. On the possible role of nootropica in geriatric prevention and therapy. Ann NY Acad Sci 786: 444-452 (1996).
165. Rose SP. 'Smart drugs': do they work? Are they ethical? Will they be legal? Nat Rev Neurosci 3: 975-979 (2002).
166. Dean W, Morgenthaler J, Fowkes SM. Phosphatidylserine smart drug II, the next generation. Health Freedom Publications: Menlo Park, CA pp 75-80 (1993).
167. Bower HM, McDonald C. A controlled trial of A.N.P. 235 ("Lucidril") in senile dementia. Med J Aust 2: 270-271 (1966).
168. Valikovics A. Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz 60(7/8): 301-310 (2007).
169. Raghavendra V, Chopra K, Kulkarni SK. Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. Neuropeptides 35: 65-69 (2001).
170. Kishore K. Possible involvement of PAF in neurobiology of learning and memory in mice. In: Punjabi University, Patiala (1998).
171. Blin O, Audebert C, Pitel S, Kaladjian A, Casse-Perrot C, Zaim M, et al. Effects of dimethylaminoethanol pyroglutamate (DMAE p- Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies. Psychopharmacology (Berl) 207(2): 201-212 (2009).
172. Parle M, Dhingra D. Ascorbic acid: a promising memory-enhancer in mice. J Pharmacol Sci 93: 129-135 (2003)
173. Saraf MK, Kishore K, Thomas KM, Sharma A, Singh M. Role of platelet activating factor in triazolobenzodiazepines-induced retrograde amnesia. Behav Brain Res 142: 31-40 (2003).
174. Cain DP. Prior non-spatial pretraining eliminates sensorimotor disturbances and impairments in water maze learning caused by diazepam. Psychopharmacology (Berl) 130: 313-319 (1997).
175. Jensen LH, Stephens DN, Sarter M, Petersen EN. Bidirectional effects of beta-carbolines and benzodiazepines on cognitive processes. Brain Res Bull 19: 359-364 (1987).
176. Hung DZ, Tsai WJ, Deng JF. Anterograde amnesia in triazolam overdose despite flumazenil treatment: a case report. Hum Exp Toxicol 11: 289-290 (1992).
177. Hlinak Z, Krejci I. Oxiracetam prevents the MK-801 induced amnesia for the elevated plus-maze in mice. Behav Brain Res 117: 147-151 (2000).
178. Hlinak Z, Krejci I. MK-801 induced amnesia for the elevated plusmaze in mice. Behav Brain Res 131: 221-225 (2002).
179. Groll-Knapp E, Haider M, Kienzl K, Handler A, Trimmel M. Changes in discrimination learning and brain activity (ERP's) due to combined exposure to NO and CO in rats. Toxicology 49: 441-447 (1988).
180. Reddy DS, Kulkarni SK. Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging- and dizocilpine-induced learning impairment. Brain Res 799: 215-229 (1998).
181. Nathan PJ, Clarke J, Lloyd J, Hutchison CW, Downey L, Stough C. The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Hum Psychopharmacol 16: 345-351 (2001).
182. Kulkarni SK, Verma A. Evidence for nootropic effect of BR-16A (Mentat), a herbal psychotropic preparation, in mice. Indian J Physiol Pharmacol 36: 29-34 (1992).
183. Das A, Shanker G, Nath C, Pal R, Singh S, Singh H. A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav 73: 893-900 (2002).
184. Maher BF, Stough C, Shelmerdine A, Wesnes K, Nathan PJ. The acute effects of combined administration of Ginkgo biloba and Bacopa monniera on cognitive function in humans. Hum Psychopharmacol 17: 163-164 (2002).
185. Nathan PJ, Tanner S, Lloyd J, Harrison B, Curran L, Oliver C, et al. Effects of a combined extract of Ginkgo biloba and Bacopa monniera on cognitive function in healthy humans. Hum Psychopharmacol 19: 91-96 (2004).
186. Kumar MH, Gupta YK. Antioxidant property of Celastrus paniculatus wild.: a possible mechanism in enhancing cognition. Phytomedicine 9: 302-311 (2002).
187. Saini K, Chaudhary A, Sharma RK. Biochemical estimation of antioxidant enzyme in cerebellum of ageing albino rats vis a vis effect of Celastrus paniculatus. Annals of Neurosciences 16(3): 103-105 (2009).
188. Snitz BE, O'Meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 302(24): 2663-2670 (2009).
189. Indurwade NH, Biyani KR. Evaluation of comparative and combined depressive effect of Brahmi, Shankhpushpi and Jatamansi in mice. Indian J Med Sci 54: 339-3341 (2000).
190. Anand A, Saraf MK, Prabhakar S. Sustained inhibition of brotizolam induced anterograde amnesia by norharmane and retrograde amnesia by l-glutamic acid in mice. Behav Brain Res 182: 12-20 (2007).
191. Saraf MK, Anand A, Prabhakar S. Scopolamine induced amnesia is reversed by Bacopa monniera through participation of kinase- CREB pathway. Neurochem Res 35(2): 279-287 (2009).
192. Saraf MK, Prabhakar S, Pandhi P, Anand A. Bacopa monniera ameliorates amnesic effects of diazepam qualifying behavioralmolecular partitioning. Neuroscience 155(2): 476-484 (2008).
193. Dhuley JN. Nootropic-like effect of ashwagandha (Withania somnifera L.) in mice. Phytother Res 15: 524-528 (2001).
194. Trigunayat A. Effect of ethanolic extract of H. perforatum on oxidative stress induced by cerebral ischemia-reperfusion in rats. Annals of Neurosciences 16(1): 6-9 (2009).
195. Bhatia AL, Jain M. Amaranthus paniculatus (Linn.) improves learning after radiation stress. J Ethnopharmacol 85: 73-77 (2003).
196. Nalini K, Karanth KS, Rao A, Aroor AR. Effects of Celastrus paniculatus on passive avoidance performance and biogenic amine turnover in albino rats. J Ethnopharmacol 47: 101-108 (1995).
197. Gattu M, Boss KL, Terry AV, Jr., Buccafusco JJ. Reversal of scopolamine-induced deficits in navigational memory performance by the seed oil of Celastrus paniculatus. Pharmacol Biochem Behav 57: 793-799 (1997).
198. Brahmi U, Srinivasan R, Komal HS, Joshi K, Gupta SK, Rajwanshi A. Comparative analysis of electron microscopy and immunocytochemistry in the cytologic diagnosis of malignant small round cell tumors. Acta Cytol 47: 443-449 (2003).
199. Lee MK, Kim SR, Sung SH, Lim D, Kim H, Choi H, et al. Asiatic acid derivatives protect cultured cortical neurons from glutamateinduced excitotoxicity. Res Commun Mol Pathol Pharmacol 108: 75-86 (2000).
200. Salimov RM. Effect of psychotropic substances on orientingexploratory behavior after startling caused by acoustic stimulation. Biull Eksp Biol Med 84: 579-582 (1977).
201. Nadkarni KM. The Indian Materia Medica. In, Columbia, MO: South Asia Books pp. 624-625 (1988).
202. Dhingra D, Parle M, Kulkarni SK. Memory enhancing activity of Glycyrrhiza glabra in mice. J Ethnopharmacol 91: 361-365 (2004).
203. Snyder JS, Hong NS, McDonald RJ, Wojtowicz JM. A role for adult neurogenesis in spatial long-term memory. Neuroscience 130(4): 843-852 (2005).
204. Denis-Donini S, Dellarole A, Crociara P, Francese MT, Bortolotto V, Quadrato G. Impaired adult neurogenesis associated with shortterm memory defects in NF-kappaB p50-deficient mice. J Neurosci 28(15): 3911-3919 (2008).
205. Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci 101(1): 343-347 (2004).
206. Höglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7(7): 726-735 (2004).
207. Clelland CD, Barker RA, Watts C. Cell therapy in Huntington disease. Neurosurg Focus 24(3/4):E9 (2008).
208. Nelson PT, Kondziolka D, Wechsler L, Goldstein S, Gebel J, De-Cesare S, Elder EM, Zhang PJ, Jacobs A, McGrogan M, Lee VM, Trojanowski JQ. Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation. Am J Pathol 160: 1201-1206 (2002).
209. SanMartin A, Borlongan CV. Cell transplantation: toward cell therapy. Cell Transplant s15(7): 665-673 (2006).
210. Nikolic WV, Hou H, Town T, Zhu Y, Giunta B, Sanberg CD, et al. Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular γ-Amyloid deposits in Alzheimer mice. Stem Cells Dev 17(3): 423-439 (2008).
211. Lee JK, Jin HK, Endo S, Schuchman EH, Carter JE, Bae JS. Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer's disease Mice by modulation of immune responses. Stem Cells 28: 329-343 (2010).
212. Wang Q, Yu S, Simonyi A, Sun GY, Sun AY. Kainic acidmediated excitotoxicity as a model for neurodegeneration. Mol Neurobiol 31: 3-16 (2005).
213. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative diseases. Annu Rev Neurosci 31: 175-193 (2008).
214. Wisniewski T, Konietzko U. Amyloid-γ immunization for Alzheimer's disease. Lancet Neurol 7: 805-811 (2008).
215. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5: 452-457 (2002).
216. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological Tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27(34): 9115-9129 (2007).
217. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3: 824-828 (2002).
218. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985 (2000).
219. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165: 283-297 (2004).
220. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452 (2003).
221. Goñi F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, et al. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One 5(10): e13391 (2010).
222. Saraf MK, Prabhakar S, Khanduja KL, Anand A. Bacopa monniera Attenuates Scopolamine-Induced Impairment of Spatial Memory in Mice. Evid Based Complement Alternat Med 2011:236186 (2011).